Amgen/KK’s Atopic Dermatitis Deal Shows OX40’s Allure, But Market Still Tough
Amgen will pay $400m upfront and up to $850m in milestones
Amgen said Phase II data are planned for the EADV 2021 meeting, but KHK4083 will need a strong showing.
You may also be interested in...
Amgen is acquiring a pipeline-in-a-pill with ChemoCentryx’s Tavneos, currently approved for ANCA-associated vasculitis, at a time when the company’s existing portfolio is struggling to maintain sales growth.
Amgen is enthusiastic about deals of all sizes, including a new Arrakis collaboration, and is interested in large transactions like its Otezla buy – but Bradway said right-priced opportunities are fewer and farther between.
Commercial EVP Murdo Gordon said launching sotorasib during the pandemic is a tougher challenge than encouraging doctors to screen lung cancer patients for KRAS G12C mutations and raising patient awareness.